Immunohistochemical Profile of Metastatic Cancer Tamotsu Sugai 1 , Noriyuki Uesugi 1 , Yasuko Fujita 1 , Ryo Sugimoto 1 , Ayaka Sato 1 , Makoto Eizuka 1 , Masamichi Suzuki 1 , Mitsumasa Osakabe 1 , Kazuyuki Ishida 1 1Department of Molecular Diagnostic Pathology, Iwate Medical University, Morioka, Japan Keyword: 転移性病変 , 腺癌 , 扁平上皮癌 , 免疫染色 pp.1052-1066
Published Date 2017/7/25
DOI https://doi.org/10.11477/mf.1403201129
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 Pathologists use various panels of IHC(immunohistochemical)stains to identify the original site for metastatic cancer, particularly for cancers of unknown origin. The role of pathological diagnosis for metastatic lesion is to determine histological diagnosis and confirm the primary lesion. IHC analysis should confirm the primary origin, which corresponds to the metastatic lesion. We aimed to summarize the use of currently available IHC markers for evaluating metastatic tumors. IHC analysis is an important pathological technique for evaluating metastatic tumors and should be used for routine histopathological diagnosis and clinical information. While a single marker may be used to support a known or suspected origin site, a carefully constructed panel is strongly recommended, particularly for tumors of morphologically uncertain lineage or origin.

Copyright © 2017, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院